• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Genmab A/S

    6/18/25 11:24:17 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GMAB alert in real time by email
    6-K 1 genmab_20250618xx6k.htm 6-K Document


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 6-K

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
    OF THE SECURITIES EXCHANGE ACT OF 1934
    FOR THE MONTH OF JUNE 2025
    COMMISSION FILE NUMBER 001-38976
    Genmab A/S
    (Exact name of Registrant as specified in its charter)
    Carl Jacobsens Vej 30
    2500 Valby
    Denmark
    +45 70 20 27 28
    (Address of principal executive offices)
    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
    Form 20-F  Form 40-F 
    This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273 and 333-284876) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.







    EXHIBIT INDEX
    ExhibitDescription of Exhibit
    3.1
    Articles of Association





    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
    GENMAB A/S
    BY:/s/ Anthony Pagano
    Name: Anthony Pagano
    Title: Executive Vice President & Chief Financial Officer

    DATE: JUNE 18, 2025


    Get the next $GMAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GMAB

    DatePrice TargetRatingAnalyst
    4/1/2025Mkt Perform → Underperform
    Bernstein
    3/11/2025Mkt Perform → Outperform
    William Blair
    2/13/2025$27.00Market Perform → Outperform
    Leerink Partners
    10/8/2024Buy
    Redburn Atlantic
    9/4/2024$31.00Equal-Weight
    Morgan Stanley
    8/20/2024Overweight → Neutral
    JP Morgan
    7/15/2024Sector Perform → Outperform
    RBC Capital Mkts
    2/23/2024$46.00 → $48.00Market Perform → Outperform
    BMO Capital Markets
    More analyst ratings

    $GMAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Transactions in Connection with Share Buy-back Program

      Company Announcement COPENHAGEN, Denmark; June 23, 2025 – Genmab A/S (NASDAQ:GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025. The following transactions were executed under the program from June 16 to June 20, 2025:  Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcement 2,080,711 2,706,417,889.19June 16, 2025XCSE1001,477.73147,772.50 BCXE0   AQEU0   TQEX0   Total100 147,772.50June 17, 2025XCSE1001,

      6/23/25 8:19:15 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Capital Increase in Genmab as a Result of Employee Warrant Exercise

      Company Announcement COPENHAGEN, Denmark; June 17, 2025 – Genmab A/S (NASDAQ:GMAB) will increase its share capital by 32,117 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 27,396 shares at DKK 1,025.00,2,790 shares at DKK 1,050.00, 150 shares at DKK 1,147.50,1,557 shares at DKK 1,161.00, and224 shares at DKK 1,334.50. Proceeds to the company are approximately DKK 33.3 million. The increase corresponds to approximately 0.05% of the company's share capital. The new shares are ord

      6/17/25 1:34:35 PM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

      Company Announcement COPENHAGEN, Denmark; June 17, 2025 – Genmab A/S (NASDAQ:GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (NASDAQ:GMAB) by managerial employees and their closely associated persons. The company's managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company's managerial employees and their closely associated persons. About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team

      6/17/25 11:37:43 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care